Project 5
项目5
基本信息
- 批准号:10674892
- 负责人:
- 金额:$ 42.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAnimal ExperimentationAnimal ExperimentsApneaAreaArousalBrain StemCarbon DioxideCell NucleusCephalicClinical TrialsCollaborationsDataDilatorDiseaseDrug CombinationsEffectivenessElectroencephalographyEventFunctional disorderGleanGoalsGrantHumanImpaired cognitionIndividualIntentionLightMeasuresMediatingMethodsMotorMuscarinicsMuscleMuscle TonusMuscle hypotoniaNeuronsNorepinephrineObstructive Sleep ApneaOutcomeOxygenPatientsPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPharyngeal structurePhenotypePhysiologicalPlacebosPredispositionPreventionREM SleepResearchSeriesSerotoninSerotonin AgonistsSerotonin AntagonistsSeveritiesSleepSleep Apnea SyndromesSleep DisordersSleep StagesStimulantTestingTrazodoneUrinary RetentionWithdrawalXerostomiaairway muscleairway obstructionantagonistatomoxetinedifferential expressiondruggable targetexperiencegabapentinhuman dataimprovedindexinginhibitormembernon rapid eye movementnovel therapeuticsoxybutyninpharmacologicpharynx musclepreventreceptorreceptor expressionrespiratoryresponsereuptakesedativeserotonin receptorside effecttraitzolpidem
项目摘要
Abstract/ Summary: Project 5
OSA is a common and debilitating condition that currently has no effective pharmacotherapy. In the previous
PPG, we identified a drug combination (atomoxetine + oxybutynin) that lowered the apnea-hypopnea index by
74% and raised the nadir oxygen saturation from 84% to 94%. Despite these encouraging results, some
patients experienced antimuscarinic side effects from oxybutynin. Furthermore, subsequent mechanistic
studies revealed that oxybutynin was acting primarily as a sedative (counteracting atomoxetine), rather than a
pharyngeal muscle stimulant. Therefore, the goal of the current grant is to find a better sedative than
oxybutynin to add to atomoxetine. This will be accomplished by first testing common, non-myorelaxing
sedatives (Aim 1). Then, in Aim 2 we will test sedatives identified from Projects 1-4 that specifically block CO2-
mediated arousals (but not CO2-mediated respiratory/pharyngeal muscle responses). As described in the
other grants accompanying this PPG, Projects 2 and 4 are expected to identify serotonin subreceptors on
parabrachial CGRP neurons (PBCGRP) that can be antagonized to prevent EEG arousal in response to elevated
CO2. Additionally, Projects 3 and 4 will focus on identifying serotonin subreceptors on a separate group of
parabrachial neurons (PBFoxP2) that could be manipulated pharmacologically to augment upper airway dilator
tone. Of note, preliminary studies suggest that PBCGRP neurons are activated by a different subset of serotonin
receptors than the PBFoxP2 neurons, thus allowing us to potentially target these two parabrachial regions
independently. Therefore, Aim 2 will test specific serotonin agonists/antagonists, with or without atomoxetine
(as necessary), to activate airway muscles without inducing arousals. Finally, in Aim 3 a one-month clinical trial
will be performed on the most effective drugs emerging from Aims 1 and 2 (if no such drugs are found, then the
original atomoxetine + oxybutynin combination will be studied). As the human component to this PPG, Project
5 will utilize the information gleaned from the animal experiments to build upon the exciting results of the
previous PPG and move the field closer towards a potential pharmacotherapy for OSA.
摘要/总结:项目5
OSA是一种常见的使人衰弱的疾病,目前还没有有效的药物治疗。上一
PPG,我们确定了一种药物组合(托莫西汀+奥昔布宁),降低呼吸暂停低通气指数,
74%,并将最低血氧饱和度从84%提高到94%。尽管取得了这些令人鼓舞的成果,
患者经历了奥昔布宁的抗毒蕈碱副作用。此外,随后的机械
研究表明,奥昔布宁主要作为镇静剂(抵消托莫西汀),而不是一种抗抑郁药。
咽肌兴奋剂因此,目前赠款的目标是找到一种比
奥昔布宁加入托莫西汀。这将通过首先测试常见的,非myorelaxing
镇静剂(目标1)。然后,在目标2中,我们将测试从项目1-4中确定的专门阻断CO2的镇静剂。
介导的觉醒(但不是CO2介导的呼吸/咽肌反应)。中所述
伴随着这个PPG的其他赠款,项目2和4预计将确定血清素亚受体,
臂旁CGRP神经元(PBCGRP),其可以被拮抗以防止响应于升高的
二氧化碳。此外,项目3和4将集中在确定血清素亚受体在一个单独的组,
臂旁神经元(PBFoxP 2),可以被操纵的背侧增加上气道扩张
语气值得注意的是,初步研究表明,PBCGRP神经元被不同的血清素亚群激活,
受体比PBFoxP 2神经元,从而使我们能够潜在地靶向这两个臂旁区域
独立地。因此,Aim 2将检测特定的5-羟色胺激动剂/拮抗剂,伴或不伴托莫西汀
(as必要的),以激活气道肌肉而不诱导觉醒。最后,在目标3中,
将对目标1和目标2中最有效的药物进行研究(如果没有发现此类药物,
将研究最初的托莫西汀+奥昔布宁组合)。作为本PPG的人类组件,项目
5将利用从动物实验中收集到的信息,建立在令人兴奋的结果的基础上,
以前的PPG和移动领域更接近一个潜在的药物治疗OSA。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID ANDREW WELLMAN其他文献
DAVID ANDREW WELLMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID ANDREW WELLMAN', 18)}}的其他基金
Predicting response to non-PAP therapies in OSA using PSG-derived endotypes
使用 PSG 衍生的内型预测 OSA 对非 PAP 疗法的反应
- 批准号:
10440108 - 财政年份:2022
- 资助金额:
$ 42.88万 - 项目类别:
Predicting response to non-PAP therapies in OSA using PSG-derived endotypes
使用 PSG 衍生的内型预测 OSA 对非 PAP 疗法的反应
- 批准号:
10705062 - 财政年份:2022
- 资助金额:
$ 42.88万 - 项目类别:
Determination of the site of pharyngeal collapse in Obstructive Sleep Apnea patients from snoring sounds
从鼾声判断阻塞性睡眠呼吸暂停患者咽部塌陷部位
- 批准号:
10515474 - 财政年份:2016
- 资助金额:
$ 42.88万 - 项目类别:
A method for measuring and modeling the physiologic traits causing sleep apnea
一种测量和模拟导致睡眠呼吸暂停的生理特征的方法
- 批准号:
8040823 - 财政年份:2011
- 资助金额:
$ 42.88万 - 项目类别:
A method for measuring and modeling the physiologic traits causing sleep apnea
一种测量和模拟导致睡眠呼吸暂停的生理特征的方法
- 批准号:
8449678 - 财政年份:2011
- 资助金额:
$ 42.88万 - 项目类别:
Validation of a Phenotype Model to Predict Response to Alternative OSA Treatments
验证表型模型以预测替代 OSA 治疗的反应
- 批准号:
9239787 - 财政年份:2011
- 资助金额:
$ 42.88万 - 项目类别:
A method for measuring and modeling the physiologic traits causing sleep apnea
一种测量和模拟导致睡眠呼吸暂停的生理特征的方法
- 批准号:
8245082 - 财政年份:2011
- 资助金额:
$ 42.88万 - 项目类别:
A method for measuring and modeling the physiologic traits causing sleep apnea
一种测量和模拟导致睡眠呼吸暂停的生理特征的方法
- 批准号:
8664909 - 财政年份:2011
- 资助金额:
$ 42.88万 - 项目类别:
相似海外基金
Development of a Drosophila-based platform to replace and reduce animal experimentation in epilepsy research
开发基于果蝇的平台来取代和减少癫痫研究中的动物实验
- 批准号:
NC/V001051/1 - 财政年份:2020
- 资助金额:
$ 42.88万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Ethical Issues in Animal Experimentation
博士论文研究:动物实验的伦理问题
- 批准号:
1424484 - 财政年份:2014
- 资助金额:
$ 42.88万 - 项目类别:
Standard Grant
Tissue formation involving stem/progenitor cell research and animal experimentation (N01)
涉及干/祖细胞研究和动物实验的组织形成(N01)
- 批准号:
30245585 - 财政年份:2006
- 资助金额:
$ 42.88万 - 项目类别:
Collaborative Research Centres
Animal experimentation and cardiac phenotyping of transgenic mouse models
转基因小鼠模型的动物实验和心脏表型分析
- 批准号:
13327687 - 财政年份:2005
- 资助金额:
$ 42.88万 - 项目类别:
Research Units
Animal Experimentation system as an infrastructure to support translational progression of diabetes research to medical practice
动物实验系统作为支持糖尿病研究向医学实践转化的基础设施
- 批准号:
17200029 - 财政年份:2005
- 资助金额:
$ 42.88万 - 项目类别:
Grant-in-Aid for Scientific Research (A)